| Similar Articles |
|---|
 |
BusinessWeek
March 22, 2004
Gene G. Marcial |
Look Who May Be Courting Bioenvision Genzyme may be interested in Bioenvision as well. Why? In 2001, Bioenvision licensed to ILEX the right to co-develop and market in the U.S. and Canada its Clorfarabine, a drug for leukemia. Bioenvision still holds the rights outside North America. The company will soon file for Food & Drug Administration approval of Clorfarabine, which has a $1 billion market potential.   |
BusinessWeek
May 2, 2005
Gene G. Marcial |
What Other Biotechs See In Bioenvision Bioenvision's childhood leukemia drug Clofarabine has received FDA approval and is expected to increase the profitability of the drug maker. |
BusinessWeek
December 6, 2004
Gene G. Marcial |
Why There's New Life At Bioenvision Bioenvision's leading product, Clofarabine, for treating leukemia in children, may get Food & Drug Administration approval soon. Is the stock a good buy? |
BusinessWeek
June 4, 2007
Gene G. Marcial |
What Big Investors See In Bioenvision Bioenvision has attracted big investors. |
The Motley Fool
December 30, 2004
Charly Travers |
Genzyme Enters Cancer Arena The approval of a new drug is a long-term opportunity for the biotech giant. |
The Motley Fool
March 2, 2004
David Nierengarten |
Genzyme's Oncology Acquisitions The biotech gobbles up two smaller firms for their cancer treatment pipelines. |
The Motley Fool
May 30, 2007
Brian Lawler |
Genzyme Gobbles Up a Partner Another day, another biotech acquisition for drugmaker Genzyme. Investors, with more than $500 million in free cash flow last year alone, Genzyme has money to spare. |
The Motley Fool
September 28, 2007
Brian Lawler |
Bioenvision Shareholder Battle Genzyme announces that it "cannot and will not" raise its $5.60-a-share bid for Bioenvision before shareholders go to vote on its proposed takeover. Investors, take note. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
The Motley Fool
October 10, 2007
Brian Lawler |
Bioenvision Demands a Recount Bioenvision decided to hold the polls open one more day, in hopes that some stockholders who hadn't yet participated would vote for their proposed acquisition by Genzyme. |
| Knowledge@Wharton |
Bristol-Myers Squibb Illustrates Woes of Ailing Pharmaceutical Industry The once-mighty pharmaceutical industry, for years the nation's most profitable, has begun to show some cracks. But no major U.S. drug maker seems to be facing more problems than Bristol-Myers Squibb. |
The Motley Fool
August 24, 2010 |
George Soros's Foolish Investments Billionaire hedge fund manager George Soros has been a net seller of U.S. equities so far in 2010. |
The Motley Fool
January 9, 2008
Brian Lawler |
Tracking Genzyme The biopharma updates investors on what to expect for 2008. |
The Motley Fool
February 19, 2010
Alex Dumortier |
Who's Right on Gold: Soros or Central Bankers? The speculator vs. the bureaucrats. |
